{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:46:53Z","timestamp":1789904813697,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clgc.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T11:01:27Z","timestamp":1557745287000},"page":"e806-e813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"given":"Thierry","family":"Landre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetan Des","family":"Guetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kader","family":"Chouahnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Fossey-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherifa","family":"Taleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.05.001_bib2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","article-title":"Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology","volume":"72","author":"Droz","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.05.001_bib3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.eururo.2017.04.010","article-title":"Prostate cancer management in an ageing population","volume":"72","author":"Grummet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.05.001_bib4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.urolonc.2009.07.015","article-title":"Prostate cancer in the elderly","volume":"27","author":"Heinzer","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.08.010","article-title":"Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"103","author":"Feyerabend","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.05.001_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41391-017-0014-9","article-title":"The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation","volume":"21","author":"McNamara","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2019.05.001_bib7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","article-title":"A\u00a0phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial","volume":"22","author":"Kamba","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.05.001_bib11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2019.05.001_bib13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.05.001_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.05.001_bib15","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","article-title":"Adding celecoxib with or without zoledronic acid for hormone-na\u00efve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial","volume":"35","author":"Mason","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","article-title":"Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial","volume":"13","author":"James","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.05.001_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.clgc.2018.05.006","article-title":"Chemotherapy-induced neutropenia and outcome in patients with metastatic castration-resistant prostate cancer treated with first-line docetaxel","volume":"16","author":"Buttigliero","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.001_bib19","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib20","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/annonc\/mdu052","article-title":"Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review","volume":"25","author":"Versteeg","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/bju.13990","article-title":"Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world","volume":"120","author":"Thompson","year":"2017","journal-title":"BJU Int"},{"issue":"8 Suppl","key":"10.1016\/j.clgc.2019.05.001_bib22","article-title":"Effects of abiraterone acetate plus prednisone\/prednisolone in high and low risk metastatic hormone sensitive prostate cancer","volume":"29","author":"Hoyle","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canep.2017.11.002","article-title":"Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer","volume":"51","author":"Dunn","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.clgc.2019.05.001_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Rydzewska","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.05.001_bib26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with\u00a0localised or metastatic, hormone-sensitive prostate cancer: a systematic\u00a0review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.05.001_bib28","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/annonc\/mdy071","article-title":"What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis","volume":"29","author":"Vale","year":"2018","journal-title":"Ann Oncol"},{"issue":"7 Suppl","key":"10.1016\/j.clgc.2019.05.001_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1200\/JCO.2019.37.7_suppl.687","article-title":"Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): the ARCHES trial","volume":"37","author":"Armstrong","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318307171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318307171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:02Z","timestamp":1761564662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318307171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1558767318307171"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.05.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736059766.793572912","asserted-by":"object"}]},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}